Advertisement

Related Videos

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Amit Sanyal, MD: A Clinician’s Perspective

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Advertisement

Advertisement




Feb
17
Today In Oncology
Oxybutynin May Improve ADT-Induced Hot Flashes in Patients With Prostate Cancer
Determining the Optimal Duration of Androgen-Deprivation Therapy Added to Definitive Radiotherapy in Localized Prostate Cancer
Induction Nivolumab Before CRT in High-Risk HPV-Driven OPC
Neoadjuvant Taxane Plus Trastuzumab and Pertuzumab With or Without Carboplatin in HER2-Positive Breast Cancer
Nonmetastatic Breast Cancer Treatment Strategies After Denosumab Discontinuation in Patients Treated With Aromatase Inhibitors
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo